GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » China Resources Boya Bio-pharmaceutical Group Co Ltd (SZSE:300294) » Definitions » Beneish M-Score

China Resources Boya Bio-pharmaceutical Group Co (SZSE:300294) Beneish M-Score

: -2.92 (As of Today)
View and export this data going back to 2012. Start your Free Trial

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.92 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for China Resources Boya Bio-pharmaceutical Group Co's Beneish M-Score or its related term are showing as below:

SZSE:300294' s Beneish M-Score Range Over the Past 10 Years
Min: -3.17   Med: -2.3   Max: -1.51
Current: -2.92

During the past 13 years, the highest Beneish M-Score of China Resources Boya Bio-pharmaceutical Group Co was -1.51. The lowest was -3.17. And the median was -2.30.


China Resources Boya Bio-pharmaceutical Group Co Beneish M-Score Historical Data

The historical data trend for China Resources Boya Bio-pharmaceutical Group Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China Resources Boya Bio-pharmaceutical Group Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.84 -3.00 -3.17 -2.53 -2.92

China Resources Boya Bio-pharmaceutical Group Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.53 -2.70 -2.74 -2.61 -2.92

Competitive Comparison

For the Biotechnology subindustry, China Resources Boya Bio-pharmaceutical Group Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


China Resources Boya Bio-pharmaceutical Group Co Beneish M-Score Distribution

For the Biotechnology industry and Healthcare sector, China Resources Boya Bio-pharmaceutical Group Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where China Resources Boya Bio-pharmaceutical Group Co's Beneish M-Score falls into.



China Resources Boya Bio-pharmaceutical Group Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of China Resources Boya Bio-pharmaceutical Group Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.8419+0.528 * 1.036+0.404 * 0.6011+0.892 * 0.9613+0.115 * 1
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.8621+4.679 * -0.051637-0.327 * 0.6882
=-2.92

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was ¥540 Mil.
Revenue was 461.581 + 649.527 + 734.944 + 805.928 = ¥2,652 Mil.
Gross Profit was 303.055 + 327.26 + 386.936 + 381.867 = ¥1,399 Mil.
Total Current Assets was ¥6,428 Mil.
Total Assets was ¥7,829 Mil.
Property, Plant and Equipment(Net PPE) was ¥677 Mil.
Depreciation, Depletion and Amortization(DDA) was ¥0 Mil.
Selling, General, & Admin. Expense(SGA) was ¥633 Mil.
Total Current Liabilities was ¥456 Mil.
Long-Term Debt & Capital Lease Obligation was ¥24 Mil.
Net Income was -226.602 + 138.149 + 155.601 + 170.317 = ¥237 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = ¥0 Mil.
Cash Flow from Operations was 116.021 + 132.522 + 170.505 + 222.679 = ¥642 Mil.
Total Receivables was ¥668 Mil.
Revenue was 675.957 + 684.026 + 744.082 + 654.636 = ¥2,759 Mil.
Gross Profit was 361.022 + 382.548 + 406.925 + 357.335 = ¥1,508 Mil.
Total Current Assets was ¥6,073 Mil.
Total Assets was ¥8,033 Mil.
Property, Plant and Equipment(Net PPE) was ¥723 Mil.
Depreciation, Depletion and Amortization(DDA) was ¥0 Mil.
Selling, General, & Admin. Expense(SGA) was ¥764 Mil.
Total Current Liabilities was ¥705 Mil.
Long-Term Debt & Capital Lease Obligation was ¥10 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(540.319 / 2651.98) / (667.642 / 2758.701)
=0.203742 / 0.242013
=0.8419

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(1507.83 / 2758.701) / (1399.118 / 2651.98)
=0.546572 / 0.527575
=1.036

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (6427.633 + 676.619) / 7828.9) / (1 - (6073.386 + 722.811) / 8033.175)
=0.092561 / 0.153984
=0.6011

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=2651.98 / 2758.701
=0.9613

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0 / (0 + 722.811)) / (0 / (0 + 676.619))
=0 / 0
=1

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(633.091 / 2651.98) / (763.906 / 2758.701)
=0.238724 / 0.276908
=0.8621

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((23.548 + 456.447) / 7828.9) / ((10.368 + 705.337) / 8033.175)
=0.061311 / 0.089094
=0.6882

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(237.465 - 0 - 641.727) / 7828.9
=-0.051637

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

China Resources Boya Bio-pharmaceutical Group Co has a M-score of -2.92 suggests that the company is unlikely to be a manipulator.


China Resources Boya Bio-pharmaceutical Group Co Beneish M-Score Related Terms

Thank you for viewing the detailed overview of China Resources Boya Bio-pharmaceutical Group Co's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


China Resources Boya Bio-pharmaceutical Group Co (SZSE:300294) Business Description

Traded in Other Exchanges
N/A
Address
Number 333, Huiquan Road, High-tech Industrial Park, Jiangxi Province, Fuzhou, CHN, 344000
China Resources Boya Bio-pharmaceutical Group Co Ltd is a China-based medical industry group that integrates biochemical drugs, chemical drugs, and active pharmaceutical ingredients. It is engaged in the provision of medical and health products and services. The product categories of the company include blood products, biochemical drugs, chemical medicines and others. Some of the company's blood products include human albumin, rabies immunoglobulin, intravenous human immunoglobulin and human fibrinogen.

China Resources Boya Bio-pharmaceutical Group Co (SZSE:300294) Headlines

No Headlines